New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
09:11 EDTXLRN, CELGAcceleron Sotatercept has growing potential, says JMP Securities
After Acceleron (XLRN) and its partner Celgene (CELG) presented data on sotatercept in patients with end-stage renal disease, JMP Securities thinks the results suggest that the treatment's potential in anemia in hemodialysis poatients is growing. The firm reiterates a $53 price target and Outperform rating on the stock.
News For XLRN;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
09:46 EDTCELGCelgene announces EC approved Abraxane
Subscribe for More Information
09:34 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MNTA CELG TSLA MCD ARUN GILD KO TWTR NFLX
07:40 EDTXLRNAcceleron reports Q4 EPS (55c), consensus (23c)
Reports Q4 revenue $3.74M, consensus $9.58M.
March 1, 2015
12:24 EDTXLRNAcceleron reports new data from Dart study on dalantercept in patients with RCC
Acceleron Pharma reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma, RCC. The preliminary data from part 1 of the DART study were presented in an oral session at the American Society of Clinical Oncology, ASCO, 2015 Genitourinary Cancers Symposium held in Orlando, Florida on February 28. “These promising response rates and progression-free survival data suggest that the dual angiogenesis blockade of ALK1 and VEGFR signaling with dalantercept and axitinib may provide additive efficacy compared to VEGFR inhibitor therapy alone,” said Matthew Sherman, M.D., Chief Medical Officer of Acceleron. “The results from part 1 of this study provide encouraging evidence of the safety and activity of this combination of two distinct anti-angiogenic agents in previously treated patients with advanced RCC,” said Martin H. Voss, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center and lead investigator for the trial. “We look forward to building on these results in the randomized part 2 of the ongoing DART trial.”
February 27, 2015
07:37 EDTCELGCelgene removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
February 25, 2015
13:44 EDTCELGCelgene price target raised to $155 from $130 at Argus
Argus increased its price target on Celgene as the firm thinks the company is "well on its way" to meeting its growth targets. The firm thinks the company reported strong Q4 results and keeps a Buy rating on the shares.
February 24, 2015
08:04 EDTCELGCelgene reports Abraxane now reimbursed in Italy as first-line treatment
Celgene International Sŕrl, a wholly owned subsidiary of Celgene Corporation, announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANE -- paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel -- in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. The reimbursement decision has been published in the Italian Official Gazette no. 30, dated February 6, 2015.
07:31 EDTCELGRBC Capital to hold a conference
Subscribe for More Information
February 23, 2015
07:22 EDTXLRNSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 20, 2015
16:03 EDTCELGOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information
February 18, 2015
16:00 EDTCELGOptions Update; February 18, 2015
Subscribe for More Information
10:05 EDTCELGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:38 EDTCELGCelgene reports FDA expands indication for Revlimid combo
Subscribe for More Information
09:37 EDTCELGOption volume leaders on open
Option volume leaders: AAPL TSLA TWTR CELG APO NFLX AXP APA LNKD C GILD according to Track Data.
06:47 EDTCELGCelgene initiated with a Buy at Canaccord
Target $156.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use